Actively Recruiting

Age: 18Years +
FEMALE
NCT07540403

Survival Analysis in patiEnts With Bad Prognosis Epithelial Ovarian CArcinoma

Led by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Updated on 2026-04-20

50

Participants Needed

1

Research Sites

101 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Ovarian carcinoma is the most lethal gynecological malignancy. Epithelial ovarian carcinoma is the gynecological malignancy with the highest mortality rate. The prognosis of patients with recurrent disease is highly heterogeneous and is typically poor in cases of ovarian carcinoma with a progression-free survival (PFS) ≤ 6 months, for which therapeutic options are limited. However, it has been shown that patients with a PFS ≤ 6 months may not respond effectively to further treatments, whereas, conversely, patients with a PFS \> 6 months could still benefit from them. The classification of patients with recurrent disease has undergone continuous evolution over time. Essential factors to consider include patient characteristics, disease stage, and the precise genetic and molecular profile of the tumor. This study aims to evaluate survival in patients experiencing recurrence of epithelial ovarian carcinoma with an unfavorable prognosis, with the objective of improving patient categorization and management.

CONDITIONS

Official Title

Survival Analysis in patiEnts With Bad Prognosis Epithelial Ovarian CArcinoma

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients diagnosed with histologically confirmed epithelial ovarian carcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma with a progression-free survival of 6 months or less
  • Age 18 years or older
  • Any FIGO stage at diagnosis
  • Signed informed consent for the use of personal data for research purposes
  • ECOG performance status of 2 or less
Not Eligible

You will not qualify if you...

  • Age under 18 years
  • Patients with non-epithelial ovarian carcinoma
  • Patients with a progression-free survival greater than 6 months

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Rome, Italy, 00136

Actively Recruiting

Loading map...

Research Team

C

Claudia Marchetti

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here